Although medications with glucagon-like peptide-1 (GLP-1) receptor agonist activity have transformed the management of obesity and shown substantial cardiometabolic benefits, unmet needs remain.
In an MRI substudy, the researchers found that survodutide improved body composition and liver fat content, with a 34% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results